Intercell AG (Intercell) is an Austria-based biotechnology company that focuses on the development and manufacturing of vaccines and monoclonal antibodies for the prevention and treatment of infectious diseases. The Company's technology platforms include Antigen Identification Program (AIP), adjuvants and a patch-based delivery system. Intercell's portfolio consists of one marketed product and six product candidates in clinical development. The Company's core product is a Japanese Encephalitis vaccine. The focus of the development portfolio of the Company is on nosocomial infections and other selected serious infectious diseases. Its development product portfolio comprises Pseudomonas aeruginosa (in Phase II/III), Clostridium difficile (in Phase I), Pandemic Flu (in Phase I), Tuberculosis (IC31) (in Phase II) and IC31 adjuvant in different products (in Phase I) programs. In May 2013, the Company announced the completion of merger of equals between the Company and Vivalis SA.
Campus Vienna Biocenter 3 1030 WIEN